How Can We Engineer CAR T Cells to Overcome Resistance?

Maya Glover,1 Stephanie Avraamides,2 John Maher1– 4 1Leucid Bio Ltd., Guy’s Hospital, London, SE1 9RT, UK; 2King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Hospital, London, SE1 9RT, UK; 3Department of Clinical Immunology and Allergy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Glover M, Avraamides S, Maher J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	chimeric antigen receptor cancer immunotherapy t-cell resistance Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/83cff87a5797459291983d07914ea971
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:83cff87a5797459291983d07914ea971
record_format	dspace
spelling	oai:doaj.org-article:83cff87a5797459291983d07914ea9712021-12-02T17:17:11ZHow Can We Engineer CAR T Cells to Overcome Resistance?1177-5491https://doaj.org/article/83cff87a5797459291983d07914ea9712021-05-01T00:00:00Zhttps://www.dovepress.com/how-can-we-engineer-car-t-cells-to-overcome-resistance-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Maya Glover,1 Stephanie Avraamides,2 John Maher1– 4 1Leucid Bio Ltd., Guy’s Hospital, London, SE1 9RT, UK; 2King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Hospital, London, SE1 9RT, UK; 3Department of Clinical Immunology and Allergy, King’s College Hospital NHS Foundation Trust, London, SE5 9RS, UK; 4Department of Immunology, Eastbourne Hospital, Eastbourne, East Sussex, BN21 2UD, UKCorrespondence: John Maher Tel +44 207 188 1468Fax +44 207 188 0919Email john.maher@kcl.ac.ukAbstract: Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.Keywords: chimeric antigen receptor, cancer, immunotherapy, T-cell, resistanceGlover MAvraamides SMaher JDove Medical Pressarticlechimeric antigen receptorcancerimmunotherapyt-cellresistanceMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 175-198 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chimeric antigen receptor cancer immunotherapy t-cell resistance Medicine (General) R5-920
spellingShingle	chimeric antigen receptor cancer immunotherapy t-cell resistance Medicine (General) R5-920 Glover M Avraamides S Maher J How Can We Engineer CAR T Cells to Overcome Resistance?
description	Maya Glover,1 Stephanie Avraamides,2 John Maher1– 4 1Leucid Bio Ltd., Guy’s Hospital, London, SE1 9RT, UK; 2King’s College London, School of Cancer and Pharmaceutical Sciences, Guy’s Hospital, London, SE1 9RT, UK; 3Department of Clinical Immunology and Allergy, King’s College Hospital NHS Foundation Trust, London, SE5 9RS, UK; 4Department of Immunology, Eastbourne Hospital, Eastbourne, East Sussex, BN21 2UD, UKCorrespondence: John Maher Tel +44 207 188 1468Fax +44 207 188 0919Email john.maher@kcl.ac.ukAbstract: Chimeric antigen receptor (CAR) T cell therapy has achieved unrivalled success in the treatment of B cell and plasma cell malignancies, with five CAR T cell products now approved by the US Food and Drug Administration (FDA). However, CAR T cell therapies for solid tumours have not been nearly as successful, owing to several additional challenges. Here, we discuss mechanisms of tumour resistance in CAR T cell therapy and the emerging strategies that are under development to engineer CAR T cells to overcome resistance.Keywords: chimeric antigen receptor, cancer, immunotherapy, T-cell, resistance
format	article
author	Glover M Avraamides S Maher J
author_facet	Glover M Avraamides S Maher J
author_sort	Glover M
title	How Can We Engineer CAR T Cells to Overcome Resistance?
title_short	How Can We Engineer CAR T Cells to Overcome Resistance?
title_full	How Can We Engineer CAR T Cells to Overcome Resistance?
title_fullStr	How Can We Engineer CAR T Cells to Overcome Resistance?
title_full_unstemmed	How Can We Engineer CAR T Cells to Overcome Resistance?
title_sort	how can we engineer car t cells to overcome resistance?
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/83cff87a5797459291983d07914ea971
work_keys_str_mv	AT gloverm howcanweengineercartcellstoovercomeresistance AT avraamidess howcanweengineercartcellstoovercomeresistance AT maherj howcanweengineercartcellstoovercomeresistance
_version_	1718381154688565248

How Can We Engineer CAR T Cells to Overcome Resistance?

Ejemplares similares